Skip to main content
Terug
Watch Compare

Caribou Biosciences, Inc.

Datakwaliteit: 100%
CRBU
Nasdaq Manufacturing Chemicals
€ 1,97
▲ € 0,02 (1,03%)
Marktkapitalisatie: 190,38 M
Prijs
€ 1,97
Marktkapitalisatie
190,38 M
Dagbereik
€ 1,93 — € 2,00
52-Weeksbereik
€ 0,71 — € 3,54
Volume
724.676
Openen € 1,95
50D / 200D Gem.
€ 1,76
11,63% above
50D / 200D Gem.
€ 1,88
4,69% above

Quick Summary

Belangrijkste Punten

Revenue grew 3,84% annually over 5 years — modest growth
Negative free cash flow of -112,35 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7,82%

Groei

Revenue Growth (5Y)
3,84%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)11,66%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-96,19%
Onder sectorgemiddelde (-53,41%)
ROIC-65,30%
Net Margin-1327,40%
Op. Margin-1329,37%

Veiligheid

Debt / Equity
N/A
Current Ratio5,54
Interest CoverageN/A

Waardering

PE (TTM)
-1,29
Boven sectorgemiddelde (-1,48)
P/B Ratio1,34
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,3 -1,5
P/B 1,3 1,6
ROE % -96,2 -53,4
Net Margin % -1327,4 -41,5
Rev Growth 5Y % 3,8 1,8
D/E — 0,3

ETFs Holding This Stock

NXTE logo NXTE AXS Green Alpha ETF
0,79% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 11,66% Revenue Growth (3Y) -43,11%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3,84% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 11,16 M Net Income (TTM) -148,13 M
ROE -96,19% ROA -71,23%
Gross Margin N/A Operating Margin -1329,37%
Net Margin -1327,40% Free Cash Flow (TTM) -112,35 M
ROIC -65,30% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,54
Interest Coverage N/A Asset Turnover 0,05
Working Capital 127,45 M Tangible Book Value 141,85 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,29 Forward P/E N/A
P/B Ratio 1,34 P/S Ratio 17,06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -59,02%
Market Cap 190,38 M Enterprise Value 179,23 M
Per Share
EPS (Diluted TTM) -1,59 Revenue / Share 0,12
FCF / Share -1,16 OCF / Share -1,15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 12,18% FCF Conversion 75,85%
SBC-Adj. FCF -126,36 M Growth Momentum 7,82

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 11,16 M 9,99 M 34,48 M 13,85 M 9,60 M
Net Income -148,13 M -149,11 M -102,07 M -99,42 M -66,92 M
EPS (Diluted) -1,59 -1,65 -1,38 -1,64 —
Gross Profit — — — — —
Operating Income -148,34 M -166,62 M -116,06 M -106,40 M -66,98 M
EBITDA — — — — —
R&D Expenses 109,44 M 130,15 M 112,08 M 82,23 M 52,26 M
SG&A Expenses — — — — —
D&A 3,65 M 3,93 M 3,53 M 1,62 M 984.000,0
Interest Expense — — — — 8.000,0
Income Tax -550.000,0 -9.000,0 193.000,0 70.000,0 321.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 175,37 M 313,31 M 432,21 M 373,77 M 442,36 M
Total Liabilities 53,19 M 60,36 M 63,81 M 72,89 M 54,53 M
Shareholders' Equity 122,18 M 252,95 M 368,40 M 300,87 M 387,83 M
Total Debt — — — — —
Cash & Equivalents 12,36 M 16,29 M 51,16 M 58,34 M 240,42 M
Current Assets 145,23 M 219,38 M 338,84 M 260,25 M 391,19 M
Current Liabilities 25,41 M 30,65 M 28,30 M 28,13 M 25,83 M